Forte Biosciences (FBRX) Cash from Operations (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Cash from Operations of 18800000.0 for Q1 2026, down 81.55% year-over-year from 101923560.21 in Q1 2025, and down 14.05% quarter-over-quarter from 16484000.0 in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Cash from Operations (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Cash from Operations for 11 consecutive years, with 18800000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 81.55% year-over-year to 18800000.0; the TTM figure through Mar 2026 stood at 59345000.0 (down 72.35% YoY), while the FY2025 annual figure was 50900000.0, down 65.56% from the prior year.
- Cash from Operations slipped to 18800000.0 in Q1 2026 per FBRX's latest filing, from 16484000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1377000.0 in Q2 2022 and bottomed at 18800000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 8078588.24 across 5 years, with a median of 8133000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 65.03% — and 2023, when it slumped 366.91%.
- Forte Biosciences' Cash from Operations stood at 2893000.0 in 2022, then slumped by 210.02% to 8969000.0 in 2023, then decreased by 11.6% to 10009000.0 in 2024, then plunged by 64.69% to 16484000.0 in 2025, then dropped by 14.05% to 18800000.0 in 2026.
- Business Quant data shows FBRX's Cash from Operations at 18800000.0 in Q1 2026, 16484000.0 in Q4 2025, and 14000000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | -22.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.70 Mn |
| Mar 31, 2026 | -18.81 Mn |
| Dec 31, 2025 | -16.48 Mn |
| Sep 30, 2025 | -14.00 Mn |
| Jun 30, 2025 | -10.06 Mn |
| Mar 31, 2025 | -10.36 Mn |
| Dec 31, 2024 | -10.01 Mn |
| Sep 30, 2024 | -8.13 Mn |
| Jun 30, 2024 | -5.94 Mn |
| Mar 31, 2024 | -6.67 Mn |
| Dec 31, 2023 | -8.97 Mn |
| Sep 30, 2023 | -9.06 Mn |
| Jun 30, 2023 | -5.48 Mn |
| Mar 31, 2023 | -5.20 Mn |
| Dec 31, 2022 | -2.89 Mn |
| Sep 30, 2022 | -1.94 Mn |
| Jun 30, 2022 | -1.38 Mn |
| Mar 31, 2022 | -1.98 Mn |
| Dec 31, 2021 | -3.58 Mn |
| Sep 30, 2021 | -5.13 Mn |